1
|
Tran C, Mahé E, Beylot-Barry M, Jullien D, Richard MA, Fougerousse AC, Bouznad A, Bulai Livideanu C, Brun A, Amelot F, Maccari F, Aubin F, Benhadou F, Paul C. Real-life management of psoriasis with biological agents during pregnancy. Ann Dermatol Venereol 2024; 151:103254. [PMID: 38554588 DOI: 10.1016/j.annder.2024.103254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Accepted: 11/07/2023] [Indexed: 04/01/2024]
Abstract
BACKGROUND French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs. MATERIAL AND METHODS We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant. RESULTS A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC. DISCUSSION The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.
Collapse
Affiliation(s)
- C Tran
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France
| | - E Mahé
- Department of Dermatology, Victor Dupouy Hospital, 95107 Argenteuil, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, 33000 Bordeaux, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - D Jullien
- Department of Dermatology, Lyon University Hospital, 69003 Lyon, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - M-A Richard
- Department of Dermatology, Marseille University Hospital, 13005 Marseille, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - A-C Fougerousse
- Department of Dermatology, Hôpital d'Instruction des Armées Bégin, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - A Bouznad
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France
| | - C Bulai Livideanu
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - A Brun
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France
| | - F Amelot
- Department of Dermatology, Carcassonne Hospital, 11000 Carcassonne, France
| | - F Maccari
- Department of Dermatology, Hôpital d'Instruction des Armées Bégin, France; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - F Aubin
- Department of Dermatology, Besançon University Hospital, 25000 Besançon, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France
| | - F Benhadou
- Department of Dermatology, Erasme Hôpital universitaire, Université Libre de Bruxelles, 1070 Brussels, Belgium; Groupe d'Etudes Multicentriques (GEM) Resopso, France
| | - C Paul
- Department of Dermatology, Toulouse University Hospital, 31400 Toulouse, France; GRPso (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), France.
| |
Collapse
|
2
|
Alif SM, Benke GP, Kromhout H, Vermeulen R, Tran C, Ronaldson K, Walker-Bone K, Woods R, Beilin L, Tonkin A, Owen AJ, McNeil JJ. Long-term occupational exposures on disability-free survival and mortality in older adults. Occup Med (Lond) 2023; 73:492-499. [PMID: 37948123 PMCID: PMC10756660 DOI: 10.1093/occmed/kqad105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2023] Open
Abstract
BACKGROUND The impact of long-term occupational exposures on health in older adults is increasingly relevant as populations age. To date, no studies have reported their impact on survival free of disability in older adults. AIMS We aimed to investigate the association between long-term occupational exposure and disability-free survival (DFS), all-cause mortality and cause-specific mortality in initially healthy older adults. METHODS We analysed data from 12 215 healthy participants in the ASPirin in Reducing Events in the Elderly (ASPREE) study whose mean age was 75 years. Their work history was collated with the 'ALOHA-plus JEM' (Job Exposure Matrix) to assign occupational exposures. The primary endpoint, DFS, was a composite measure of death, dementia or persistent physical disability. The secondary endpoint, mortality, was classified according to the underlying cause. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals, adjusted for confounders. RESULTS A total of 1835 individuals reached the DFS endpoint during the median 4.7 years follow-up period. Both ever-high and cumulative exposure to all dusts and all pesticides during a person's working years were associated with reduced DFS. Compared to no exposure, men with high exposure to dusts and pesticides had a reduced DFS. Neither of these exposures were significantly associated with all-cause mortality. Men with high occupational exposure to solvents and women exposed to dusts experienced higher all-cause and cancer-related mortality. CONCLUSIONS Long-term occupational exposure to all dusts and pesticides was associated with a reduced DFS and increased mortality in community-dwelling healthy older adults.
Collapse
Affiliation(s)
- S M Alif
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
- School of Health Sciences, The University of Melbourne, Melbourne, Victoria 3000, Australia
- Institute of Health and Wellbeing, Federation University Australia, Berwick, Victoria 3806, Australia
| | - G P Benke
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - H Kromhout
- Environmental Epidemiology Division, Institute for Risk Assessment Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - R Vermeulen
- Environmental Epidemiology Division, Institute for Risk Assessment Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - C Tran
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - K Ronaldson
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - K Walker-Bone
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - R Woods
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - L Beilin
- School of Medicine, The University of Western Australia, Perth, Western Australia 6009, Australia
| | - A Tonkin
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - A J Owen
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| | - J J McNeil
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
| |
Collapse
|
3
|
Turk-Adawi K, Ghisi GLM, Tran C, Heine M, Raidah F, Contractor A, Grace SL. First report of the International Council of Cardiovascular Prevention and Rehabilitation's Registry (ICRR). Expert Rev Cardiovasc Ther 2023; 21:357-364. [PMID: 37024997 DOI: 10.1080/14779072.2023.2199154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/08/2023]
Abstract
OBJECTIVES Cardiac rehabilitation - programs comprehensively delivering outpatient secondary prevention - is under-available and under-studied in the resource-poor settings where it is needed most. This report summarizes the governance, participating sites, patient characteristics and outcomes, as well as knowledge translation activities during first year of operation of ICCPR's registry, namely the International Cardiac Rehab Registry. METHODS A pilot study was undertaken with five centers, demonstrating feasibility, satisfaction with the on-boarding processes, as well as data quality. RESULTS Fourteen centers have been engaged from all regions but Europe; Data have been entered on >1000 patients (18.1% female; mean age = 57.6), of whom 62.4% completed their programs and 19.9% dropped out for work or clinical reasons. Post-program, completers had significantly better work status, functional capacity, medication adherence, physical activity levels, diet, as well as lower tobacco use than non-completers (all p < 0.05). A site Certification program was developed and piloted, with five centers now recognized for their quality, given they met over 70% of the 13 internationally agreed standards based on Registry data and a virtual site assessment. CONCLUSION Annual assessments have started. Quality improvement activities will soon be underway. We continue to invite new programs, supporting development in resource-poor settings to the benefit of patients served.
Collapse
Affiliation(s)
| | - G L M Ghisi
- Faculty of Health, York University, Toronto, ON, Canada
- KITE Research Institute- Toronto Rehabilitation Institute, University Health Network, Toronto, Canada
| | - C Tran
- Faculty of Health, York University, Toronto, ON, Canada
| | - M Heine
- UMC Utrecht, University Medical Center Utrecht, Utrecht, Netherlands
| | - F Raidah
- Faculty of Health, York University, Toronto, ON, Canada
| | - A Contractor
- Rehabilitation and Sports Medicine, Sir H.N Reliance Foundation Hospital, Mumbai, India
| | - S L Grace
- Faculty of Health, York University, Toronto, ON, Canada
- KITE Research Institute- Toronto Rehabilitation Institute, University Health Network, Toronto, Canada
- Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
4
|
Grace E, Tran C, Long C, Rech M. 256 Trends in Opioid Overdoses During the COVID-19 Pandemic. Ann Emerg Med 2022. [PMCID: PMC9519216 DOI: 10.1016/j.annemergmed.2022.08.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
5
|
Petrosyan V, Tran C, Whitfield P. 699 Accounting for Fixation Shrinkage in Temporal Artery Biopsy. Br J Surg 2022. [DOI: 10.1093/bjs/znac269.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Abstract
Aim
Ascertain the length shrinkage of Temporal Artery Biopsy (TAB) following fixation to inform current practice and ensure samples taken are in keeping with the British Society of Rheumatology Recommendations.
The British Society of Rheumatology (2020) recommends a sample size of at least 1cm post fixation to be of diagnostic value for Giant Cell Arteritis (GCA). Formalin has been shown to cause 20–30% volume shrinkage of histopathological specimens. Shrinkage relating to length, specifically with TABs was shown to be approximately 8% based on a sample size of 13 patients.
Method
A consecutive sample of patients undergoing TAB between January-December 2021 were analysed. Those with measurements documented in the op note were compared to the post fixation measurement documented in the histopathology report. Statistical analysis included demographic data as well p values calculated for the differences in length.
Results
Forty Seven patients were treated for TAB, M:F (1:1.26), Mean Age=73.06 (47–94). Mean pre-fixation length = 26.84mm (SD-8.38), Mean post-fixation length = 20.27mm (SD-8.72). Overall shrinkage was calculated at 25% with a p value of 0.0046, confirming a significant difference between the two sample groups.
Conclusion
This sample demonstrates there to be a clear difference between the two measurements, with a significant percentage shrinkage. Appreciation of shrinkage is vital in obtaining a suitable sample to ensure diagnostic value and appropriate patient care. Further evaluation, both prospective and retrospective is underway with the results pending.
Collapse
Affiliation(s)
- V Petrosyan
- York District Hospital , York , United Kingdom
| | - C Tran
- York District Hospital , York , United Kingdom
| | - P Whitfield
- York District Hospital , York , United Kingdom
| |
Collapse
|
6
|
Moroni JL, Tsoi S, Wenger II, Tran C, Plastow GS, Charagu P, Dyck MK. The influence of litter birth weight phenotype on embryonic and placental development at day 30 of gestation in multiparous purebred Large White sows. Anim Reprod Sci 2022; 244:107035. [PMID: 35901575 DOI: 10.1016/j.anireprosci.2022.107035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 07/11/2022] [Accepted: 07/19/2022] [Indexed: 11/01/2022]
Abstract
The aim of this study was to understand the intrauterine biological processes associated with the low litter birth weight phenotype in pigs. Analyses were conducted on reproductive data from a purebred Large White maternal line to identify sows (>2 parities) with repeatable high or low litter birth weight phenotype (HLBWP or LLBWP). A total of 40 sows were selected (n = 20 HLBWP and n = 20 LLBWP) and bred with semen from purebred Large White boars of proven fertility. Sows were euthanized on day 28-30 of gestation (day 29.5 ± 0.6) and samples of placenta and embryos collected. Total number of embryos (TNE), embryonic weight (EW), embryonic viability, and crown-rump (CRL) measurements were recorded, along with the ovulation rate (OR) and allantochorionic fluid volume (AFV). No significant difference was detected (P > 0.05) in OR, TNE, and number of viable embryos on day 30 of gestation between the two groups. There was no significant difference in EW (LLBWP: 0.80 ± 0.05 g; HLBWP: 0.88 ± 0.04 g, P = 0.18) or CRL (LLBWP: 21.5 ± 0.7 mm; HLBWP: 21.9 ± 0.68 mm, P = 0.46). Placental development represented by the average AFV was significantly lower in the LLBWP compared to HLBWP (LLBWP: 131 ± 9.82 mL; HLBWP: 149 ± 9.39 mL, P = 0.03). In conclusion, placental development may be the main factor causing lower BW of entire litters in LLBWP sows.
Collapse
Affiliation(s)
- J L Moroni
- Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB, Canada.
| | - S Tsoi
- Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB, Canada
| | - I I Wenger
- Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB, Canada
| | - C Tran
- Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB, Canada
| | - G S Plastow
- Livestock Gentec, Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada
| | - P Charagu
- Hypor, Hendrix Genetics, Regina, SK, Canada
| | - M K Dyck
- Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
7
|
McIntyre C, McLeod M, Tutt T, Petersen A, Lepori-Bui N, Patel S, Monterola G, Siddiqui A, Villar K, Tran C, Bainter C, Pham T, Diaz N, Lim L, Dibian Z, Wang L, Meyer E. Process Development and Manufacturing: GROWING A CELL THERAPY FACILITY TO SUPPORT SPONSORED CLINICAL TRIALS AND COMMERCIAL CELL THERAPY PRODUCTS. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00449-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
8
|
Tran C, Lu T, Doughty J, Khan Z, Noctor A, Movahedi S. Dental public health in action: foundation dentists' delivery of an oral health promotion outreach project for people experiencing homelessness in London. Community Dent Health 2021; 38:5-9. [PMID: 33507652 DOI: 10.1922/cdh_000782020tran05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Dental public health in action: foundation dentists' delivery of an oral health promotion outreach project for people experiencing homelessness in London.Within a decade, the UK has seen a dramatic increase in homelessness. This is defined as being without an available home that could reasonably be occupied. The increase has been driven by increasing poverty, welfare reform, cuts to public services and lack of affordable housing (Bramley et al., 2015; Fitzpatrick et al., 2013; Fitzpatrick et al., 2018). Rough sleeping in England alone has increased by 2,909 people or 165% since 2010 (Ministry of Housing, Communities and Local Government, 2018). This increase has been particularly visible in London (National Audit Office, 2018), where approximately a quarter of the country's rough sleepers reside (Ministry of Housing, Communities and Local Government, 2018).
Collapse
Affiliation(s)
- C Tran
- London & Kent, Surrey and Sussex, Health Education England, United Kingdom
| | - T Lu
- London & Kent, Surrey and Sussex, Health Education England, United Kingdom
| | - J Doughty
- Faculty for Homeless and Inclusion Health, Pathway, United Kingdom
| | - Z Khan
- Institute of Epidemiology and Health Care, University College London, United Kingdom
| | - A Noctor
- Find&Treat Outreach Service, University College London Hospitals, United Kingdom
| | - S Movahedi
- London & Kent, Surrey and Sussex, Health Education England, United Kingdom
| |
Collapse
|
9
|
Boyd AT, Moore B, Shah M, Tran C, Kirking H, Cavanaugh JS, Al-Samarrai T, Pathmanathan I. Implementing TB preventive treatment within differentiated HIV service delivery models in global programs. Public Health Action 2020; 10:104-110. [PMID: 33134124 DOI: 10.5588/pha.20.0014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 06/15/2020] [Indexed: 11/10/2022] Open
Abstract
Global HIV program stakeholders, including the US President's Emergency Plan for AIDS Relief (PEPFAR), are undertaking efforts to ensure that eligible people living with HIV (PLHIV) receiving antiretroviral treatment (ART) receive a course of TB preventive treatment (TPT). In PEPFAR programming, this effort may require providing TPT not only to newly diagnosed PLHIV as part of HIV care initiation, but also to treatment-experienced PLHIV stable on ART who may not have been previously offered TPT. TPT scale-up is occurring at the same time as a trend to provide more person-centered HIV care through differentiated service delivery (DSD). In DSD, PLHIV stable on ART may receive less frequent clinical follow-up or receive care outside the traditional clinic-based model. The misalignment between traditional delivery of TPT and care delivery in innovative DSD may require adaptations to TPT delivery practices for PLHIV. Adaptations include components of planning and operationalization of TPT in DSD, such as determination of TPT eligibility and TPT initiation, and clinical management of PLHIV while on TPT. A key adaptation is alignment of timing and location for TPT and ART prescribing, monitoring, and dispensing. Conceptual examples of TPT delivery in DSD may help program managers operationalize TPT in HIV care.
Collapse
Affiliation(s)
- A T Boyd
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - B Moore
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - M Shah
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - C Tran
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - H Kirking
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - J S Cavanaugh
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - T Al-Samarrai
- Office of the Global AIDS Coordinator, Washington DC, USA
| | - I Pathmanathan
- Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|
10
|
Torres E, Tran C, Valin N, Le Marec F, Pifaut C, Lacombe K, Meynard J. Évaluation des connaissances sur le tabagisme chez les patients vivant avec le VIH. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
11
|
Pater C, Baker G, de La Bourdonnaye G, Elamin A, Goujon C, Haziza C, Heremans A, Hoeng J, Ivanov N, Luedicke F, Maeder S, Phillips B, Picavet P, Pouly S, Poussin C, Pratte P, Tran C, Vanscheeuwiijck P, Peitsch M. 716 Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Disease: Translating Basic Science into Clinical Benefit. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Tran C, Haddad M, Ratovelomanana-Vidal V. Ruthenium-Catalyzed, Microwave-Mediated [2+2+2] Cycloaddition: A Useful Combination for the Synthesis of 2-Aminopyridines. Synlett 2019. [DOI: 10.1055/s-0037-1611920] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
A ruthenium-catalyzed [2+2+2] cycloaddition between α,ω-diynes and cyanamides is reported under microwave irradiation to access 2-aminopyridines. In contrast to the classical thermal conditions, this atom-economical sustainable protocol allows access to diverse functionalized 2-aminopyridine derivatives with high yields and excellent regioselectivities in MeTHF with short reaction times.
Collapse
Affiliation(s)
| | | | - V. Ratovelomanana-Vidal
- PSL Research University, Chimie ParisTech, CNRS, Institute of Chemistry for Life and Health Sciences
| |
Collapse
|
13
|
Pageon H, Azouaoui A, Zucchi H, Ricois S, Tran C, Asselineau D. Potentially beneficial effects of rhamnose on skin ageing: an in vitro and in vivo study. Int J Cosmet Sci 2019; 41:213-220. [PMID: 30845349 DOI: 10.1111/ics.12523] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Accepted: 03/04/2019] [Indexed: 12/18/2022]
Abstract
OBJECTIVE Recent findings showed that skin ageing preferentially affects human papillary dermal fibroblasts suggesting that the papillary dermis represents a critical zone altered by skin ageing. Based on these findings, we investigated the potential anti-ageing effect of rhamnose. METHODS We investigated the potential anti-ageing effect of rhamnose using in vitro reconstructed skin containing fibroblasts obtained either from young or old donors, and in vivo clinical investigation. RESULTS We detected positive effects of rhamnose in both epidermal and dermal compartments of in vitro reconstructed skin. Moreover, we were able to show that such in vitro findings were also obtained in vivo including an effect on collagen IV and procollagen I production. CONCLUSION We provide evidence that rhamnose has a potentially beneficial effect on papillary dermis and dermal-epidermal junction, both of the areas which are affected by skin ageing.
Collapse
Affiliation(s)
- H Pageon
- L'Oréal Research and Innovation, L'Oréal, 1 avenue Eugène Schueller, 93360, Aulnay-sous-Bois, France
| | - A Azouaoui
- L'Oréal Research and Innovation, L'Oréal, 1 avenue Eugène Schueller, 93360, Aulnay-sous-Bois, France
| | - H Zucchi
- L'Oréal Research and Innovation, L'Oréal, 1 avenue Eugène Schueller, 93360, Aulnay-sous-Bois, France
| | - S Ricois
- L'Oréal Research and Innovation, L'Oréal, 1 avenue Eugène Schueller, 93360, Aulnay-sous-Bois, France
| | - C Tran
- L'Oréal Research and Innovation, L'Oréal, 1 avenue Eugène Schueller, 93360, Aulnay-sous-Bois, France
| | - D Asselineau
- L'Oréal Research and Innovation, L'Oréal, 1 avenue Eugène Schueller, 93360, Aulnay-sous-Bois, France
| |
Collapse
|
14
|
Rubio-Gozalbo ME, Haskovic M, Bosch AM, Burnyte B, Coelho AI, Cassiman D, Couce ML, Dawson C, Demirbas D, Derks T, Eyskens F, Forga MT, Grunewald S, Häberle J, Hochuli M, Hubert A, Huidekoper HH, Janeiro P, Kotzka J, Knerr I, Labrune P, Landau YE, Langendonk JG, Möslinger D, Müller-Wieland D, Murphy E, Õunap K, Ramadza D, Rivera IA, Scholl-Buergi S, Stepien KM, Thijs A, Tran C, Vara R, Visser G, Vos R, de Vries M, Waisbren SE, Welsink-Karssies MM, Wortmann SB, Gautschi M, Treacy EP, Berry GT. The natural history of classic galactosemia: lessons from the GalNet registry. Orphanet J Rare Dis 2019; 14:86. [PMID: 31029175 PMCID: PMC6486996 DOI: 10.1186/s13023-019-1047-z] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 03/12/2019] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Classic galactosemia is a rare inborn error of carbohydrate metabolism, caused by a severe deficiency of the enzyme galactose-1-phosphate uridylyltransferase (GALT). A galactose-restricted diet has proven to be very effective to treat the neonatal life-threatening manifestations and has been the cornerstone of treatment for this severe disease. However, burdensome complications occur despite a lifelong diet. For rare diseases, a patient disease specific registry is fundamental to monitor the lifespan pathology and to evaluate the safety and efficacy of potential therapies. In 2014, the international Galactosemias Network (GalNet) developed a web-based patient registry for this disease, the GalNet Registry. The aim was to delineate the natural history of classic galactosemia based on a large dataset of patients. METHODS Observational data derived from 15 countries and 32 centers including 509 patients were acquired between December 2014 and July 2018. RESULTS Most affected patients experienced neonatal manifestations (79.8%) and despite following a diet developed brain impairments (85.0%), primary ovarian insufficiency (79.7%) and a diminished bone mineral density (26.5%). Newborn screening, age at onset of dietary treatment, strictness of the galactose-restricted diet, p.Gln188Arg mutation and GALT enzyme activity influenced the clinical picture. Detection by newborn screening and commencement of diet in the first week of life were associated with a more favorable outcome. A homozygous p.Gln188Arg mutation, GALT enzyme activity of ≤ 1% and strict galactose restriction were associated with a less favorable outcome. CONCLUSION This study describes the natural history of classic galactosemia based on the hitherto largest data set.
Collapse
Affiliation(s)
- M E Rubio-Gozalbo
- Department of Pediatrics and Clinical Genetics, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, P. Debyelaan 25, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
| | - M Haskovic
- Department of Pediatrics and Clinical Genetics, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, P. Debyelaan 25, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands
| | - A M Bosch
- Amsterdam UMC, University of Amsterdam, Pediatric Metabolic Diseases, Emma Children's Hospital, Amsterdam, Netherlands
| | - B Burnyte
- Institute of Biomedical Sciences of the Faculty of Medicine of Vilnius University, Vilnius, Lithuania
| | - A I Coelho
- Department of Pediatrics and Clinical Genetics, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, P. Debyelaan 25, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands
| | - D Cassiman
- Metabolic Center, Department of Gastroenterology-Hepatology, Leuven University Hospitals and KU Leuven, Leuven, Belgium
| | - M L Couce
- Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, S. Neonatology, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, CIBERER, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - C Dawson
- Department of Endocrinology, Queen Elizabeth Hospital Birmingham, London, UK
| | - D Demirbas
- Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - T Derks
- Section of Metabolic Diseases, Beatrix Children's Hospital, and Groningen University Institute for Drug Exploration (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - F Eyskens
- Antwerp University Hospital, Antwerp, Belgium
| | - M T Forga
- Hospital Clinic Barcelona, Barcelona, Spain
| | - S Grunewald
- Metabolic Medicine Department, Great Ormond Street Hospital, Institute for Child Health UCL, London, UK
| | - J Häberle
- Division of Metabolism and Children's Research Center, University Children's Hospital, Zurich, Switzerland
| | - M Hochuli
- Department of Endocrinology, Diabetes, and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
| | - A Hubert
- APHP, HUPS, Hôpital Antoine Béclère, Centre de Référence Maladies Héréditaires Hépatiques, Clamart, France.,Université Paris Sud-Paris Saclay, and INSERM U 1195, Paris, France
| | - H H Huidekoper
- Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
| | - P Janeiro
- Department of Pediatrics, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal
| | - J Kotzka
- Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany
| | - I Knerr
- National Centre for Inherited Metabolic Disorders, Temple Street Children's University Hospital, Temple Street, Dublin, Ireland
| | - P Labrune
- APHP, HUPS, Hôpital Antoine Béclère, Centre de Référence Maladies Héréditaires Hépatiques, Clamart, France.,Université Paris Sud-Paris Saclay, and INSERM U 1195, Paris, France
| | - Y E Landau
- Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - J G Langendonk
- Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - D Möslinger
- Department for Pediatrics and Adolescent Medicine, Inborn Errors of Metabolism, Medical University of Vienna, Vienna, Austria
| | - D Müller-Wieland
- Clinical Research Center, Department of Medicine I, University Hospital RWTH Aachen, Aachen, Germany
| | - E Murphy
- Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK
| | - K Õunap
- Department of Clinical Genetics, United Laboratories and Institute of Clinical Medicine, Tartu University Hospital, Tartu, Estonia
| | - D Ramadza
- Department of Pediatrics, University Hospital Centre, Zagreb, Croatia
| | - I A Rivera
- Research Institute for Medicines (iMed.ULisboa), and Department of Biochemistry and Human Biology, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
| | - S Scholl-Buergi
- Universitätsklink für Pädiatrie, Tirol Kliniken GmbH, Innsbruck, Austria
| | - K M Stepien
- Mark Holland Metabolic Unit, Adult Inherited Metabolic Disorders Department, Salford Royal NHS Foundation Trust, Salford, M6 8HD, UK
| | - A Thijs
- Vrije Universiteit Amsterdam, Internal Medicine, Amsterdam UMC, Amsterdam, Netherlands
| | - C Tran
- Center for Molecular Diseases, Division of Genetic Medicine, University Hospital Lausanne, Lausanne, Switzerland
| | - R Vara
- Department of Paediatric Inherited Metabolic Disease, Evelina London Children's Hospital, London, UK
| | - G Visser
- Department of Pediatrics, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - R Vos
- Department of Methodology and Statistics, CAPHRI School for Primary Care and Public Health, Faculty Health Medicine and Life Sciences, Maastricht, The Netherlands
| | - M de Vries
- Department of Pediatrics, Radboud University Medical Center, Nijmegen, The Netherlands
| | - S E Waisbren
- Department of Pediatrics, Division of Genomics and Genetics, Harvard Medical School and Boston Children's Hospital, Boston, USA
| | - M M Welsink-Karssies
- Amsterdam UMC, University of Amsterdam, Pediatric Metabolic Diseases, Emma Children's Hospital, Amsterdam, Netherlands
| | - S B Wortmann
- University Children's Hospital, Parcelsus Medical University (PMU), Salzburg, Austria
| | - M Gautschi
- Department of Pediatrics and Institute of Clinical Chemistry, Inselspital, University Hospital Bern, Bern, Switzerland
| | - E P Treacy
- Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, Dublin 7, Ireland
| | - G T Berry
- Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
15
|
Tran C, Ha N. A Variable Neighborhood Search Algorithm for Solving the Steiner Minimal Tree Problem in Sparse Graphs. EAI Endorsed Transactions on Context-aware Systems and Applications 2018. [DOI: 10.4108/eai.6-2-2019.156534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
16
|
Choi YH, Zhang X, Tran C, Skinner B. Expression profiles of host immune response-related genes against HEV genotype 3 and genotype 1 infections in rhesus macaques. J Viral Hepat 2018; 25. [PMID: 29532615 PMCID: PMC8996335 DOI: 10.1111/jvh.12890] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Hepatitis E virus (HEV) genotype (gt) 3 infection is food-borne causing sporadic infections in older individuals and gt1 infection is waterborne, often causing epidemics affecting primarily young adults. Although HEV infection causes self-limited disease, gt3 induces chronic infection in immunocompromised individuals. Hepatic host gene expression against gt3 infection remains unknown. Host gene expression profiles for HEV gt1 (n = 3) and gt3 (n = 7) infections were analysed in the livers of experimentally infected rhesus macaques. HEV RNA was detected from 2 to 24 days after inoculation (DAI) in stool and serum, elevated alanine aminotransferase (ALT) activity was detected from 7 to 31 DAI, and anti-HEV antibody became detectable between 12 and 42 DAI. All 10 animals cleared the infection between 34 and 68 DAI. We found that 24%, 48% and 41% of hepatic immune response genes against gt3 infection were upregulated during the early, peak and decline phases of HEV RNA replication. For gt1 infection, 25% of hepatic immune response-related genes were downregulated during early viremia, but 6%, 34% and 37% of genes were upregulated at the early, peak and during decline of HEV RNA replication, respectively. Our study demonstrated distinct differences in the expression profiles of host immune response-related genes of HEV gt3 and gt1 infections in experimentally infected rhesus macaques.
Collapse
Affiliation(s)
- Y. H. Choi
- Laboratory Branch, Division of Viral Hepatitis, NCHHSTP, CDC, Atlanta, GA, USA
| | - X. Zhang
- Laboratory Branch, Division of Viral Hepatitis, NCHHSTP, CDC, Atlanta, GA, USA
| | - C. Tran
- Laboratory Branch, Division of Viral Hepatitis, NCHHSTP, CDC, Atlanta, GA, USA
| | - B. Skinner
- Comparative Medicine Branch, Division of Scientific Resources, NCEZID, CDC, Atlanta, GA, USA
| |
Collapse
|
17
|
Lu H, Lu H, Vaucher J, Tran C, Vollenweider P, Castioni J. [Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review]. Rev Med Interne 2018; 40:20-27. [PMID: 30031565 DOI: 10.1016/j.revmed.2018.06.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 05/28/2018] [Accepted: 06/17/2018] [Indexed: 01/30/2023]
Abstract
Thiamine-responsive megaloblastic anemia (TRMA), also known as Rogers syndrome, is a rare autosomal recessive disease characterized by three main components: megaloblastic anemia, diabetes mellitus and sensorineural deafness. Those features occur in infancy but may arise during adolescence. Diagnosis relies on uncovering genetic variations (alleles) in the SLC19A2 gene, encoding for a high affinity thiamine transporter. This transporter is essentially present in hematopoietic stem cells, pancreatic beta cells and inner ear cells, explaining the clinical manifestations of the disease. Based on a multidisciplinary approach, treatment resides on lifelong thiamine oral supplementation at pharmacological doses, which reverses anemia and may delay development of diabetes. However, thiamine supplementation does not alleviate already existing hearing defects.
Collapse
Affiliation(s)
- H Lu
- Service de médecine interne, centre hospitalier universitaire vaudois (CHUV), rue du Bugnon, 46, 1011 Lausanne, Suisse.
| | - H Lu
- Service des urgences adultes, centre hospitalier universitaire Antoine-Béclère, Assistance publique-Hôpitaux de Paris (AP-HP), 157, rue de la Porte de Trivaux, 92140 Clamart, France
| | - J Vaucher
- Service de médecine interne, centre hospitalier universitaire vaudois (CHUV), rue du Bugnon, 46, 1011 Lausanne, Suisse
| | - C Tran
- Service de médecine génétique, centre hospitalier universitaire vaudois (CHUV), rue du Bugnon, 46, 1011 Lausanne, Suisse
| | - P Vollenweider
- Service de médecine interne, centre hospitalier universitaire vaudois (CHUV), rue du Bugnon, 46, 1011 Lausanne, Suisse
| | - J Castioni
- Service de médecine interne, centre hospitalier universitaire vaudois (CHUV), rue du Bugnon, 46, 1011 Lausanne, Suisse
| |
Collapse
|
18
|
Abstract
We describe herein a three-step synthesis of aliphatic sulfinates. This cost-effective method involves the use of 2-mercaptobenzothiazole under mild conditions and exhibits good yields (up to 78% over three steps). This approach provides an access to a wide range of functionalized sulfinates. A good tolerance with respect to diverse functional groups (alkene, alkyne, ether, acetal) was also noted.
Collapse
Affiliation(s)
- M. Haddad
- PSL Research University, Chimie ParisTech, CNRS, Institut de Recherche de Chimie Paris
| | - P. Phansavath
- PSL Research University, Chimie ParisTech, CNRS, Institut de Recherche de Chimie Paris
| | | | - C. Tran
- PSL Research University, Chimie ParisTech, CNRS, Institut de Recherche de Chimie Paris
| | - B. Flamme
- PSL Research University, Chimie ParisTech, CNRS, Institut de Recherche de Chimie Paris
| | - A. Chagnes
- PSL Research University, Chimie ParisTech, CNRS, Institut de Recherche de Chimie Paris
- Université de Lorraine, CNRS
| |
Collapse
|
19
|
Sanders M, Bruin R, Tran C. Technologie des chambres d’inhalation à valve : efficacité à faible débit (nourrissons). Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Azouaoui A, Tran C, Gueniche A, Cassin G, Laboureau J, Jouy C. 052 Microemulsion: A new-type of formulation dedicated to skin anti-aging products. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
21
|
Davidson WM, Morimoto AK, Moya MM, Schoeneman JL, Thunborg S, Starr GP, Sami SM, Tran C, Hsu MC, Naito N, Sakuma A, Shigeno K, Mori N, Ha JJ, Aldemir T, Hussein FM, Obeid MA, El-Malahy KS, Binney SE, Harris RD, Uda T, Ozawa Y, Iba H, Wanner H, Tallent OK, McDaniel EW, Dodson KE, Godsey TT, Murray AP, Braester C, Thunvik R, Kim HC, Hsiao MY, Levine SH. Authors. NUCL TECHNOL 2017. [DOI: 10.13182/nt87-a34014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
22
|
Sami SM, Tran C. A Digital Computer Model for Predicting Reactor Coolant Pump Behavior. NUCL TECHNOL 2017. [DOI: 10.13182/nt87-a34016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Samir M. Sami
- University of SherbrookeDepartment of Mechanical Engineering, Sherbrooke, Quebec, Canada, J IK 2R1
| | - C. Tran
- University of SherbrookeDepartment of Mechanical Engineering, Sherbrooke, Quebec, Canada, J IK 2R1
| |
Collapse
|
23
|
Sharma R, Ahlm C, Ostergaard L, Dowell A, Tran C, Thomas S, Eymin C. Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously. Hum Vaccin Immunother 2016; 11:1709-16. [PMID: 25996838 DOI: 10.1080/21645515.2015.1019187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
Hepatitis B vaccines do not generate protective immune responses in older adults as effectively as they do in children and young adults. Improved formulations of existing vaccines may have the potential to improve this. This study investigated the persistence of serum antibodies against hepatitis B surface antigens (anti-HBs) 3.1-3.5 years following primary vaccination with 3 doses of HBvaxPRO® or Engerix B™ in healthy adults aged ≥ 50 years who were further challenged with 1 dose of recombinant hepatitis B antigen. This was an open-label extension study. Individuals (N = 204) with a mean (standard deviation) age at enrollment of 63.7 (7.0) years receiving HBvaxPRO® or Engerix B™ in a randomized, double-blind primary study were challenged with 1 dose of HBvaxPRO® (10 μg). Anti-HBs were measured pre- and 30 days post-challenge. 45.5% (34.8, 56.4 [95% CI]) of individuals who received HBvaxPRO® in the per protocol set (PPS) had anti-HBs titers ≥ 10 mIU/mL pre-challenge and 85.2% (76.1, 91.9) 1-month post-challenge. In those who received Engerix B™ in the primary vaccination series, the results were 58.8% (48.6, 68.5) and 88.3% (80.5, 93.8), respectively. The challenge dose of HBvaxPRO® was generally well tolerated. Subjects aged ≥ 50 years receiving a challenge dose of HBvaxPRO® demonstrated immune memory against hepatitis B 3 years after a 3-dose primary. The safety profile of this challenge dose of HBvaxPRO® was consistent with the well-established safety profile of the vaccine HBvaxPRO®.
Collapse
Key Words
- AE, adverse event
- CI, confidence interval
- GMT, geometric mean titer
- HBsAg, hepatitis B surface antigen
- PPS, per protocol set
- SAE, serious adverse event
- SAS, safety analysis set
- SD, standard deviation
- SPR, seroprotection rate
- adult
- anti-HBs, antibody to HBsAg
- hepatitis B
- immunity
- persistence
- vaccination
Collapse
Affiliation(s)
- Rajiv Sharma
- a Sea Road Surgery; Bexhill-on-Sea , East Sussex , UK
| | | | | | | | | | | | | |
Collapse
|
24
|
Jackson CB, Bauer MF, Schaller A, Kotzaeridou U, Ferrarini A, Hahn D, Chehade H, Barbey F, Tran C, Gallati S, Haeberli A, Eggimann S, Bonafé L, Nuoffer JM. A novel mutation in BCS1L associated with deafness, tubulopathy, growth retardation and microcephaly. Eur J Pediatr 2016; 175:517-25. [PMID: 26563427 DOI: 10.1007/s00431-015-2661-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Revised: 08/27/2015] [Accepted: 10/26/2015] [Indexed: 12/22/2022]
Abstract
UNLABELLED We report a novel homozygous missense mutation in the ubiquinol-cytochrome c reductase synthesis-like (BCS1L) gene in two consanguineous Turkish families associated with deafness, Fanconi syndrome (tubulopathy), microcephaly, mental and growth retardation. All three patients presented with transitory metabolic acidosis in the neonatal period and development of persistent renal de Toni-Debré-Fanconi-type tubulopathy, with subsequent rachitis, short stature, microcephaly, sensorineural hearing impairment, mild mental retardation and liver dysfunction. The novel missense mutation c.142A>G (p.M48V) in BCS1L is located at a highly conserved region associated with sorting to the mitochondria. Biochemical analysis revealed an isolated complex III deficiency in skeletal muscle not detected in fibroblasts. Native polyacrylamide gel electrophoresis (PAGE) revealed normal super complex formation, but a shift in mobility of complex III most likely caused by the absence of the BCS1L-mediated insertion of Rieske Fe/S protein into complex III. These findings expand the phenotypic spectrum of BCS1L mutations, highlight the importance of biochemical analysis of different primary affected tissue and underline that neonatal lactic acidosis with multi-organ involvement may resolve after the newborn period with a relatively spared neurological outcome and survival into adulthood. CONCLUSION Mutation screening for BCS1L should be considered in the differential diagnosis of severe (proximal) tubulopathy in the newborn period. WHAT IS KNOWN • Mutations in BCS1L cause mitochondrial complex III deficiencies. • Phenotypic presentations of defective BCS1L range from Bjornstad to neonatal GRACILE syndrome. What is New: • Description of a novel homozygous mutation in BCS1L with transient neonatal acidosis and persistent de Toni-Debré-Fanconi-type tubulopathy. • The long survival of patients with phenotypic presentation of severe complex III deficiency is uncommon.
Collapse
Affiliation(s)
- C B Jackson
- Institute of Clinical Chemistry, University Hospital Berne, Berne, Switzerland. .,Research Program for Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
| | - M F Bauer
- Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany
| | - A Schaller
- Division of Human Genetics, Berne, University Hospital Berne, Berne, Switzerland
| | | | - A Ferrarini
- Ospedale Regionale di Bellinzona, Bellinzona, Switzerland
| | - D Hahn
- Institute of Clinical Chemistry, University Hospital Berne, Berne, Switzerland
| | - H Chehade
- Pediatric Nephrology Unit, CHUV, Lausanne, Switzerland
| | - F Barbey
- Center for Molecular Diseases, Lausanne University Hospital, Lausanne, Switzerland
| | - C Tran
- Center for Molecular Diseases, Lausanne University Hospital, Lausanne, Switzerland
| | - S Gallati
- Division of Human Genetics, Berne, University Hospital Berne, Berne, Switzerland
| | - A Haeberli
- Institute of Clinical Chemistry, University Hospital Berne, Berne, Switzerland
| | - S Eggimann
- Institute of Clinical Chemistry, University Hospital Berne, Berne, Switzerland
| | - L Bonafé
- Center for Molecular Diseases, Lausanne University Hospital, Lausanne, Switzerland
| | - J-M Nuoffer
- Institute of Clinical Chemistry, University Hospital Berne, Berne, Switzerland
| |
Collapse
|
25
|
Theodore B, Balsiger D, Tran C, McReynolds J, Lober W, Tauben D, Sullivan M. (122) Prevalence of post-traumatic stress disorder and its association with outcome measures in a general chronic pain population. The Journal of Pain 2016. [DOI: 10.1016/j.jpain.2016.01.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
26
|
Schulze A, Tran C, Levandovskiy V, Patel V, Cortez MA. Systemic availability of guanidinoacetate affects GABAA receptor function and seizure threshold in GAMT deficient mice. Amino Acids 2016; 48:2041-7. [PMID: 26898547 DOI: 10.1007/s00726-016-2197-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Accepted: 02/08/2016] [Indexed: 11/29/2022]
Abstract
Deficiency of guanidinoacetate methyltransferase (GAMT) causes creatine depletion and guanidinoacetate accumulation in brain with the latter deemed to be responsible for the severe seizure disorder seen in affected patients. We studied electrical brain activity and GABAA mediated mechanisms of B6J.Cg-Gamt(tm1Isb) mice. Electrocorticographic (ECoG) monitoring of pharmacological treatments with ornithine (5 % in drinking water for 5-18 days) and/or Picrotoxin (PTX) (a GABAA receptor antagonist) (1.5 mg/kg, I.P.) in Gamt(MUT) and Gamt(WT) groups [n = 3, mean age (SEM) = 6.9 (0.2) weeks]. Mice were fitted with two frontal and two parietal epidural electrodes under ketamine/xylazine anesthesia. Baseline and test recordings were performed for determination of seizure activity over a 2 h period. The ECoG baseline of Gamt(MUT) exhibited an abnormal monotonous cortical rhythm (7-8 Hz) with little variability during awake and sleep states compared to wild type recordings. Ornithine treatment and also PTX administration led to a relative normalization of the Gamt(MUT) ECoG phenotype. Gamt(WT) on PTX exhibited electro-behavioral seizures, whereas the Gamt(MUT) did not have PTX induced seizures at the same PTX dose. Gamt(MUT) treated with both ornithine and PTX did not show electro-behavioral seizures while ornithine elevated the PTX seizure threshold of Gamt(MUT) mice even further. These data demonstrate: (1) that there is expression of electrical seizure activity in this Gamt-deficient transgenic mouse strain, and (2) that the systemic availability of guanidinoacetate affects GABAA receptor function and seizure thresholds. These findings are directly and clinically relevant for patients with a creatine-deficiency syndrome due to genetic defects in GAMT and provide a rational basis for a combined ornithine/picrotoxin therapeutic intervention.
Collapse
Affiliation(s)
- A Schulze
- Program of Genetics and Genome Biology, Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. .,Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
| | - C Tran
- Program of Genetics and Genome Biology, Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.,Center for Molecular Diseases, Lausanne University Hospital, Lausanne, Switzerland
| | - V Levandovskiy
- Program of Genetics and Genome Biology, Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada
| | - V Patel
- Program of Genetics and Genome Biology, Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada
| | - M A Cortez
- Department of Pediatrics, University of Toronto, Toronto, ON, Canada.,Program of Brain and Behavior Neuroscience and Mental Health, Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
| |
Collapse
|
27
|
Sanders MJ, Bruin R, Tran C. M32 Design and development of a new pMDI training aid. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Flaugher B, Diehl HT, Honscheid K, Abbott TMC, Alvarez O, Angstadt R, Annis JT, Antonik M, Ballester O, Beaufore L, Bernstein GM, Bernstein RA, Bigelow B, Bonati M, Boprie D, Brooks D, Buckley-Geer EJ, Campa J, Cardiel-Sas L, Castander FJ, Castilla J, Cease H, Cela-Ruiz JM, Chappa S, Chi E, Cooper C, da Costa LN, Dede E, Derylo G, DePoy DL, de Vicente J, Doel P, Drlica-Wagner A, Eiting J, Elliott AE, Emes J, Estrada J, Fausti Neto A, Finley DA, Flores R, Frieman J, Gerdes D, Gladders MD, Gregory B, Gutierrez GR, Hao J, Holland SE, Holm S, Huffman D, Jackson C, James DJ, Jonas M, Karcher A, Karliner I, Kent S, Kessler R, Kozlovsky M, Kron RG, Kubik D, Kuehn K, Kuhlmann S, Kuk K, Lahav O, Lathrop A, Lee J, Levi ME, Lewis P, Li TS, Mandrichenko I, Marshall JL, Martinez G, Merritt KW, Miquel R, Muñoz F, Neilsen EH, Nichol RC, Nord B, Ogando R, Olsen J, Palaio N, Patton K, Peoples J, Plazas AA, Rauch J, Reil K, Rheault JP, Roe NA, Rogers H, Roodman A, Sanchez E, Scarpine V, Schindler RH, Schmidt R, Schmitt R, Schubnell M, Schultz K, Schurter P, Scott L, Serrano S, Shaw TM, Smith RC, Soares-Santos M, Stefanik A, Stuermer W, Suchyta E, Sypniewski A, Tarle G, Thaler J, Tighe R, Tran C, Tucker D, Walker AR, Wang G, Watson M, Weaverdyck C, Wester W, Woods R, Yanny B. THE DARK ENERGY CAMERA. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/0004-6256/150/5/150] [Citation(s) in RCA: 580] [Impact Index Per Article: 64.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
29
|
Gajdos V, Vidor E, Richard P, Tran C, Sadorge C. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV. Vaccine 2015; 33:3988-96. [PMID: 26087294 DOI: 10.1016/j.vaccine.2015.06.036] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 06/01/2015] [Accepted: 06/04/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION This follow-up study assessed the 5-year persistence of vaccine-induced antibodies (Td-IPV or DT-IPV) and the immune response to a booster dose of DTaP-IPV. METHODS This was an open-label, parallel-group (two arms), multicentre trial performed at 44 study sites in France. Children aged 11-13 years, of either sex, who received Td-IPV (Revaxis(®)) and DT-IPV (DT Polio(®)) vaccines at 6 years of age in one previous open-label trial with no further vaccination against diphtheria, tetanus, pertussis or poliomyelitis, were enrolled. All participants received a single intramuscular booster dose (0.5mL) of DTaP-IPV vaccine (Tetravac-Acellulaire(®)). Study endpoints were based on antibody persistence and post-booster immune responses. Safety was monitored throughout the study. Descriptive statistics were used for all analyses. RESULTS Of the 758 children included in the previous study, 274 were included in this follow-up study; 129 had previously been vaccinated with Td-IPV, and 145 had previously received DT-IPV. At least 96.5% of participants in both groups presented an anti-diphtheria and anti-tetanus concentration ≥0.01IU/mL, and anti-poliovirus types 1-3 titres≥8 (1/dilution). Following vaccination with DTaP-IPV, anti-diphtheria and anti-tetanus antibody concentrations ≥0.1IU/mL and anti-poliovirus types 1-3 antibody titres ≥8 (1/dilution) were achieved in all participants. DTaP-IPV was well tolerated in this study. There were no serious adverse events during the study, and no participant withdrew because of adverse events. DISCUSSION The present study confirmed the long-term immunity conferred by Td-IPV when given as a booster dose, and supports the use of Td-IPV as a second booster at 6 years of age in children previously vaccinated against diphtheria, tetanus and poliomyelitis types 1-3.
Collapse
Affiliation(s)
- Vincent Gajdos
- Paediatric Department, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris-Sud, 157 Rue de la Porte de Trivaux, 92140 Clamart, France; Université Paris Sud, Le Kremlin Bicêtre, Orsay France.
| | - Emmanuel Vidor
- Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69367 Lyon Cedex 07, France.
| | - Patrick Richard
- Sanofi Pasteur MSD, 162 avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France.
| | - Clément Tran
- Sanofi Pasteur MSD, 162 avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France.
| | - Christine Sadorge
- Sanofi Pasteur MSD, 162 avenue Jean Jaurès, CS 50712, 69367 Lyon Cedex 07, France.
| |
Collapse
|
30
|
Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants. Vaccine 2015; 33:2379-86. [DOI: 10.1016/j.vaccine.2015.02.070] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 02/26/2015] [Accepted: 02/26/2015] [Indexed: 11/29/2022]
|
31
|
Tran C, Barbey F, Pitteloud N, Philippe J, Kern I, Bonafé L. [Inborn errors of metabolism: transition from childhood to adulthood]. Rev Med Suisse 2015; 11:445-449. [PMID: 25915985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Inborn errors of metabolism (IEM) are due to mutations of genes coding for enzymes of intermediary metabolism and are classified into 3 broad categories: 1) intoxication, 2) energy defect and 3) cellular organelles synthesis or catabolism defect. Improvements of therapy over these last 20 years has improved prognosis of children with IEM. These children grow up and should have their transition to specialized adult care. Adult patients with IEM are a relatively new phenomenon with currently only limited knowledge. Extrapolated pediatric guidelines are applied to the adult population taking into account adult life stages (social independence, pregnancy, aging process and potential long-term complications).
Collapse
|
32
|
Makhlouf AM, Meyer P, Tran C, Pataky Z, Philippe J, Pichard C, Dibner C. P107: Étude du rythme circadien des patients sains, obèses et diabétiques de type 2 : Une étude préliminaire in vitro. NUTR CLIN METAB 2014. [DOI: 10.1016/s0985-0562(14)70749-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Tran C, Wijeysundera HC, Qui F, Tu JV, Bhatia RS. Comparing the Ambulatory Care and Outcomes for Rural and Urban Patients With Chronic Ischemic Heart Disease: A Population-Based Cohort Study. Circ Cardiovasc Qual Outcomes 2014; 7:835-43. [DOI: 10.1161/circoutcomes.114.001076] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Ferrera G, Gajdos V, Thomas S, Tran C, Fiquet A. Safety of a refrigerator-stable varicella vaccine (VARIVAX®) in healthy 12- to 15-month-old children – a randomized, double-blind, cross-over study. Human Vaccines 2014; 5:455-60. [DOI: 10.4161/hv.8269] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
35
|
Tran C, Yazdanpanah M, Kyriakopoulou L, Levandovskiy V, Zahid H, Naufer A, Isbrandt D, Schulze A. Stable isotope dilution microquantification of creatine metabolites in plasma, whole blood and dried blood spots for pharmacological studies in mouse models of creatine deficiency. Clin Chim Acta 2014; 436:160-8. [DOI: 10.1016/j.cca.2014.05.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2013] [Revised: 05/04/2014] [Accepted: 05/06/2014] [Indexed: 10/25/2022]
|
36
|
Makhlouf AM, Meyer P, Tran C, Pataky Z, Philippe J, Pichard C, Dibner C. PP248-SUN: Outstanding abstract: Circadian Rhythms in Healthy, Type 2 Diabetic and Obese Patients: A Preliminary in Vitro Study. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50289-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Rodriguez A, Tran C, Self E. Does cue processing accelerate the onset of inhibition of return? J Vis 2014. [DOI: 10.1167/14.10.1153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
38
|
Koyama RV, Silva LF, Henriques VB, Tran C, Yoshikawa GT. Pure red cell aplasia associated with systemic lupus erythematosus. Acta Reumatol Port 2014; 39:265-268. [PMID: 25326408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Pure red cell aplasia is a rare condition described in patients with autoimmune diseases such as systemic lupus erythematosus. Bone marrow examination of a 52-year-old female showed selective severe hypoplasia, scarce hematopoietic reserves, and no abnormality in other cell lineages, which are findings compatible with red cell aplasia. This condition has not responded to corticosteroids, cytotoxic drugs or intravenous immunoglobulin. After therapy with high doses of glucocorticoids, cyclophosphamide, and immunoglobulin failed, she was treated with human recombinant erythropoietin, monthly pulses of methylprednisolone, and cyclophosphamide, simultaneously. Data on treatment with erythropoietin for pure red cell aplasia associated with systemic lupus erythematosus is limited, but it appears to be reasonable to try in refractory cases.
Collapse
Affiliation(s)
| | | | | | - C Tran
- Michigan State University College of Human Medicine (MSUCHM)
| | | |
Collapse
|
39
|
Tran C, Wigg KG, Zhang K, Cate-Carter TD, Kerr E, Field LL, Kaplan BJ, Lovett MW, Barr CL. Association of the ROBO1 gene with reading disabilities in a family-based analysis. Genes Brain Behav 2014; 13:430-8. [PMID: 24612512 PMCID: PMC4930671 DOI: 10.1111/gbb.12126] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 01/10/2014] [Accepted: 02/18/2014] [Indexed: 01/28/2023]
Abstract
Linkage studies have identified a locus on chromosome 3 as reading disabilities (RD) and speech and sound disorder (SSD) susceptibility region, with both RD and SSD sharing similar phonological processing and phonological memory difficulties. One gene in this region, roundabout homolog 1 (ROBO1), has been indicated as a RD candidate and has shown significant association with measures of phonological memory in a population-based sample. In this study, we conducted a family-based association analysis using two independent samples collected in Toronto and Calgary, Canada. Using the two samples, we tested for association between ROBO1 single nucleotide polymorphisms (SNPs) and RD, along with quantitative measures for reading, spelling and phonological memory. One SNP, rs331142, which was selected based on its correlation with ROBO1 expression in brain tissue, was found to be significantly associated with RD in the Toronto sample with over transmission of the minor C allele (P = 0.001), correlated with low expression. This SNP is located ~200 bp from a putative enhancer and results for a marker within the enhancer, rs12495133, showed evidence for association with the same allele in both the Toronto and Calgary samples (P = 0.005 and P = 0.007). These results support previous associations between ROBO1 and RD, as well as correlation with low gene expression, suggesting a possible mechanism of risk conferred by this gene.
Collapse
Affiliation(s)
- C. Tran
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario
- Institute of Medical Science, University of Toronto, Toronto, Ontario
| | - K. G. Wigg
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario
| | - K. Zhang
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario
| | - T. D. Cate-Carter
- Neurosciences & Mental Health Program, The Hospital for Sick Children, Toronto, Ontario
| | - E. Kerr
- Neurosciences & Mental Health Program, The Hospital for Sick Children, Toronto, Ontario
| | - L. L. Field
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia
| | - B. J. Kaplan
- Department of Paediatrics, Faculty of Medicine, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada
| | - M. W. Lovett
- Neurosciences & Mental Health Program, The Hospital for Sick Children, Toronto, Ontario
| | - C. L. Barr
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario
- Institute of Medical Science, University of Toronto, Toronto, Ontario
- Neurosciences & Mental Health Program, The Hospital for Sick Children, Toronto, Ontario
| |
Collapse
|
40
|
Tran C, Michelet JF, Simonetti L, Fiat F, Garrigues A, Potter A, Segot E, Watson REB, Griffiths CEM, de Lacharrière O. In vitro and in vivo studies with tetra-hydro-jasmonic acid (LR2412) reveal its potential to correct signs of skin ageing. J Eur Acad Dermatol Venereol 2013; 28:415-23. [PMID: 23701744 DOI: 10.1111/jdv.12113] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Accepted: 01/16/2013] [Indexed: 12/01/2022]
Abstract
BACKGROUND LR2412, a synthetic derivative of jasmonic acid, improved the reconstruction and homeostasis of our organotypic skin models. OBJECTIVES The need for efficient 'anti-ageing' treatments, in particular for the management of photoaged skin, prompted us to investigate this new ingredient for its potential to correct signs of skin ageing in vitro and in vivo and to identify its mode of action. RESULTS In vitro, penetration of LR2412 was evaluated using a Franz diffusion cell on excised human skin. Its exfoliating properties and interactions with the stratum corneum were studied using electron microscopy and X-ray diffraction. Experiments were performed on a human reconstructed skin model. In vivo, the effects of LR2412 on steroid-induced skin atrophy, a clinical skin ageing model, were assessed vs. vehicle. A patch test study evaluated its effect on deposition of fibrillin-rich microfibrils in the papillary dermis in clinically photoaged volunteers. A clinical study on the appearance of crow's feet wrinkles was conducted over 3 months of daily application. Penetration studies revealed that LR2412 reaches viable epidermis and superficial dermis, which are skin targets of anti-ageing actives. Within the upper layers of the stratum corneum LR2412 accelerates desquamation and improves the mechanical properties. At the dermal-epidermal junction of reconstructed skin, collagen IV, laminin-5 and fibrillin were stimulated. In vivo, LR2412 reversed steroid-induced atrophy. The patch test model confirms the deposition of fibrillin-rich microfibrils, then an in use clinical study revealed that it reduced facial wrinkles. CONCLUSIONS The in vitro and in vivo data demonstrate that based on its multiple interactions within human skin, LR2412 has potential to partially correct the signs of ageing in intrinsically and photoaged skin.
Collapse
Affiliation(s)
- C Tran
- L'Oréal Research and Innovation, Clichy, Aulnay sous Bois, Chevilly-Larue, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Tran C, Gagnon F, Wigg K, Feng Y, Gomez L, Cate-Carter T, Kerr E, Field L, Kaplan B, Lovett M, Barr C. A family-based association analysis and meta-analysis of the reading disabilities candidate gene DYX1C1. Am J Med Genet B Neuropsychiatr Genet 2013; 162B:146-56. [PMID: 23341075 PMCID: PMC5381964 DOI: 10.1002/ajmg.b.32123] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2012] [Accepted: 11/07/2012] [Indexed: 11/11/2022]
Abstract
Reading disabilities (RD) have a significant genetic basis and have shown linkage to multiple regions including chromosome 15q. Dyslexia susceptibility 1 candidate gene 1 (DYX1C1) on chromosome 15q21 was originally proposed as a candidate gene with two potentially functional polymorphisms at the -3G/A and 1249G/T positions showing association with RD. However, subsequent studies have yielded mixed results. We performed a literature review and meta-analysis of the -3G/A and 1249G/T polymorphisms, including new unpublished data from two family-based samples. Ten markers in DYX1C1 were genotyped in the two independently ascertained samples. Single marker and -3G/A:1249G/T haplotype analyses were performed for RD in both samples, and quantitative trait analyses using standardized reading-related measures was performed in one of the samples. For the meta-analysis, we used a random-effects model to summarize studies that tested for association between -3G/A or 1249G/T and RD. No significant association was found between the DYX1C1 SNPs and RD or any of the reading-related measures tested after correction for the number of tests performed. The previously reported risk haplotype (-3A:1249T) was not biased in transmission. A total of 9 and 10 study samples were included in the meta-analysis of the -3G/A and 1249G/T polymorphisms, respectively. Neither polymorphism reached statistical significance, but the heterogeneity for the 1249G/T polymorphism was high. The results of this study do not provide evidence for association between the putatively functional SNPs -3G/A and 1249G/T and RD.
Collapse
Affiliation(s)
- C. Tran
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
| | - F. Gagnon
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - K.G. Wigg
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
| | - Y. Feng
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
| | - L. Gomez
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
| | - T.D. Cate-Carter
- Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - E.N. Kerr
- Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - L.L. Field
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
| | - B.J. Kaplan
- Alberta Children’s Hospital and Department of Paediatrics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - M.W. Lovett
- Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - C.L. Barr
- Genetics and Development Division, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada,Program in Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Ontario, Canada,Correspondence to: Dr. C.L. Barr, Genetics and Development Division, The Toronto Western Hospital, 399 Bathurst St., Room MP14-302, Toronto, ON, Canada M5T 2S8.
| |
Collapse
|
42
|
|
43
|
Berthet N, Paulous S, Coffey LL, Frenkiel MP, Moltini I, Tran C, Matheus S, Ottone C, Ungeheuer MN, Renaudat C, Caro V, Dussart P, Gessain A, Desprès P. Resequencing microarray method for molecular diagnosis of human arboviral diseases. J Clin Virol 2012; 56:238-43. [PMID: 23219893 DOI: 10.1016/j.jcv.2012.10.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2012] [Accepted: 10/31/2012] [Indexed: 12/29/2022]
Abstract
BACKGROUND Resequencing DNA microarray (RMA) technology uses probes designed to identify a panel of viral sequences. It can be used for detecting emerging viruses by revealing the nucleotide polymorphisms within the target of interest. OBJECTIVES/STUDY DESIGN As a new tool for molecular diagnosis of arbovirus infection, high density PathogenID v2.0 RMA (PID2-RMA) was assessed for the detection and genetic analysis of dengue, West Nile, and Chikungunya viruses in spiked blood samples or sera from individuals infected with dengue virus. Viral RNAs extracted from biological samples were retrotranscribed into cDNA and amplified using the Phi 29 polymerase-based method. This amplified cDNA was used for hybridization on PID2-RMA. RESULTS A good specificity of RMA-based detection was demonstrated using a panel of arboviruses including Dengue, West Nile and Chikungunya viruses. This technology was also efficient for the detection and genetic analysis of the different serotypes of dengue virus in sera of infected patients. Furthermore, the mixing of dengue, West Nile and Chikungunya prototype viruses within a single sample of human blood did not interfere with the sensitivity of PID2-RMA. CONCLUSIONS Our data show that high density PID2-RMA was suitable for the identification of medically important arboviruses. It appears to be particularly adapted to the genetic analysis of dengue, West Nile, and Chikungunya viruses in urgent clinical situations where the rapid identification and characterization of the pathogen is essential.
Collapse
Affiliation(s)
- N Berthet
- Institut Pasteur, Epidemiology and Physiopathology of Oncogenic Viruses Unit, 28 rue du Docteur Roux, F75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Wong NHY, Tran C, Pukallus M, Holcombe T, Seow WK. A three-year retrospective study of emergency visits at an oral health clinic in south-east Queensland. Aust Dent J 2012; 57:132-7. [PMID: 22624751 DOI: 10.1111/j.1834-7819.2012.01688.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND There is little information available regarding dental emergencies for children in Australia. The aim of this study was to investigate the reasons for dental emergency cases which were treated at a public oral health clinic in a low socioeconomic district in south-east Queensland. METHODS From a register kept at a public oral health clinic, we analysed the monthly number of emergency visits for children over a three-year period (January 2008 to August 2010) with respect to numbers treated, reasons for presentation and types of treatment rendered. RESULTS During the period 2008-2010, there was a mean of 196 ± 86 cases presenting for emergency care each month. The proportions of the various types of emergencies remained fairly consistent over the three-year period, with the majority presenting for caries related problems (74-75%), followed by trauma (8-9%), orthodontic treatment related (2-5%) and other reasons (16-11%). Between 8-11% of cases were preschool children who were added to the waitlist for treatment for caries under general anaesthesia at the public hospital. CONCLUSIONS Trends in the past three years at a public oral health clinic in a low socioeconomic district in south-east Queensland show that dental caries constitute nearly three-quarters of all paediatric emergency appointments.
Collapse
Affiliation(s)
- N H Y Wong
- Centre for Paediatric Dentistry, School of Dentistry, The University of Queensland, Brisbane
| | | | | | | | | |
Collapse
|
45
|
Abstract
Angiogenesis has been shown to be important in tumor growth and metastasis. Thalidomide, an oral sedative, has recently been found to inhibit angiogenesis. We therefore set out to ask whether thalidomide can be used as therapy for breast cancer. In a mouse model of breast cancer, we found that thalidomide alone did not suppress tumor growth. However, mice treated with thalidomide in combination with cytoxan and adriamycin had significantly smaller tumors than those given the two chemotherapeutic agents alone (3,432 +/- 303 mm(3) versus 4,643 +/- 203 mm(3), p = 0.0005). We proceeded to administer thalidomide together with chemotherapy to seven breast cancer patients in the context of a Phase I trial. Side effects attributed to thalidomide were minimal, and included constipation and a rash. We concluded that an approach at cancer therapeutics combining an antiangiogenic agent such as thalidomide with conventional chemotherapy may be feasible and deserves further studies.
Collapse
Affiliation(s)
- M Nguyen
- UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIAT THERAPY,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Köhler Ballan B, Tran C, Perrenoud L, Vischer UM. [How to prevent severe hypoglycemia in older patients with type 2 diabetes]. Rev Med Suisse 2011; 7:2166-2169. [PMID: 22164672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Severe hypoglycemia is a feared complication of treatment in older diabetic patients (> 75 years) and a limiting factor for good glycemic control. Its real incidence is not well studied and probably underestimated. Cognitive impairment, malnutrition and/or cachexia, polypharmacy and a recent hospitalization are risk factors for severe hypoglycemia specific for older patients. Cognitive impairment screening can identify patients unable to manage their treatment. Simplification of treatment and/or transferring its execution to relatives must then be considered. Prevention also involves the detection of malnutrition and comorbidities, Age-adjusted therapeutic targets (HbA1c 7-8%) are important to avoid an exceedingly strict glycemic control. However, giving up on good glycemic control is not an adequate prevention strategy in itself.
Collapse
Affiliation(s)
- B Köhler Ballan
- Service d'endocrinologie, diabétologie et nutrition, HUG, 1211 Genève 14.
| | | | | | | |
Collapse
|
47
|
Watson A, Paz N, Tran C, Self E. Misbinding of color and motion: Effect of color variation and solidity of object. J Vis 2011. [DOI: 10.1167/11.11.870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
48
|
Tran C, Boulvain M, Philippe J. [Management of gestational diabetes: current knowledge and future perspectives]. Rev Med Suisse 2011; 7:1250-1254. [PMID: 21751721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Gestational diabetes (GDM) is one of the most common complications of pregnancy and its prevalence is increasing continuously. Diagnosis, screening of GDM and therapeutic interventions are topics of ongoing controversies and uncertainty that have contributed to make the management of GDM complex and different from one country to another. Recent studies, such as ACHOIS and HAPO, have contributed to better define screening criteria and international recommendations and have demonstrated that management of GDM, including glucose monitoring, diet and insulin if needed, is worthwhile. This article summarizes the current status of screening, management of GDM and postpartum follow-up.
Collapse
Affiliation(s)
- C Tran
- Service d'endocrinologie, diabétologie et nutrition, HUG, 1211 Genève 14.
| | | | | |
Collapse
|
49
|
Gariani K, Tran C, Philippe J. [Glycated hemoglobin: a new screening tool?]. Rev Med Suisse 2011; 7:1238-1242. [PMID: 21751719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Evaluation of mean glycemic control in diabetic patients is possible with the measure of glycosylated hemoglobin (HbA1c). Recently, new recommendations were made giving this test a diagnostic value for diabetes. HbA1c is the best prediction parameter of complications linked to diabetes; its measure is relatively accurate and simple. Nevertheless, the threshold value is arbitrary and a standardized method of dosage still remains limited. The aim of this article is to analyze the implementation of this dosage, its advantages and disadvantages as a diagnostic tool in comparison with plasma glycaemia, and current data concerning its sensibility, specificity and clinical implication.
Collapse
Affiliation(s)
- K Gariani
- Service de médecine interne générale, HUG, 1211 Geneve 14.
| | | | | |
Collapse
|
50
|
Kato Y, Mascaux C, Wynes MW, Reyna Asuncion B, Tran C, Yoshida K, Matsubayashi J, Nakajima E, Ohira T, Nagao T, Furukawa K, Ikeda N, Hirsch FR. The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA technology. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10556] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|